Isodiol International Inc. (OTC: ISOLF), a global cannabidiol (CBD) innovator specializing in the development of pharmaceutical and wellness products, announced May 1 that it had completed the merger acquisition of 100% of KURE™ Corp., a leading specialty vape retailer headquartered in Charlotte, North Carolina, with retail locations throughout the United States. Both Isodiol and KURE™ are clients of Level Brands Inc. (NYSE American: LEVB), an innovative marketing and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses.
Why It Matters: Craig Brewer, CEO of KURE™, said, “Our customers have been requesting CBD products for some time. We have been very diligent in making sure our products are safe and meet all applicable standards. In joining the Isodiol family, we will now be able to provide our devout customers the very best CBD products on the market.”
Marcos Agramont, CEO of Isodiol, said, “KURE™ adds a vertical dimension to our business plan that no other CBD company can claim. We now take CBD from the plant and deliver it to the end customer through our own retail platform. Our new brand of kathy ireland® Health & Wellness products will debut in all KURE stores shortly. We share KURE™’s philosophy of ‘customer first,’ and we know our customers are very excited about the new choices in the KURE™ stores. Craig and his management team will continue to consolidate the retail vape industry throughout North America under the KURE™ platform, and we expect our store count to increase over the next 18 to 24 months.”
Key Quote: “This merger was a triumph for all parties and shows Level Brands’ commitment to our clients. Isodiol and KURE™ are long-term clients of Level Brands, and helping bring them together in such a powerful way is an extraordinary achievement.” Martin Sumichrast, Chairman & CEO of Level Brands Inc.
Disclosure
(Level Brands [NYSE: LEVB] is a client of RedChip Companies. LEVB agreed to pay RedChip a monthly cash fee and 5,000 shares of Rule 144 stock for four months of RedChip investor awareness services.)
TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Disruptive Growth & Healthcare Conference, held May 8-9, 2018 at Reed Smith LLP in New York City.
Disruptive Growth & Healthcare Conference Disruptive ImmunoTherapies Panel Date: Wednesday, May 9th, 2018 Time: 9:30 AM ET Location: Track 2 | Room C/D
TapImmune Company Presentation Date: Wednesday, May 9th, 2018 Time: 11:35 AM ET Location: Track 1 | Room A/B
The Backstory: TapImmune is in four active Phase 2 clinical trials (six clinical trials in total) in the $100+ billion market for immunotherapy cancer drugs. The global market for cancer drugs is projected to top $150 billion by 2020 (IMS Health), and much of the growth is being driven by constant innovations in cancer immunotherapy. Currently, the company is advancing its robust mid-stage clinical pipeline focused on breast and ovarian cancer.
Disclosure
(TapImmune, Inc. [NASDAQ: TPIV] is a client of RedChip Companies, Inc. TPIV agreed to pay RedChip Companies, Inc., a monthly cash fee for (4) months of RedChip investor awareness services.)
Covanta Holding (NYSE: CVA), a world leader in sustainable waste and energy solutions, reported last week its Q1 results. Revenue was up double digits, hitting $458 million, while net income surged to $201 million, up from a net loss of $52 million in the year-ago period.
Why It Matters: Covanta is a proven leader in operating energy-from-waste systems and looks geared up for a period of sustained growth, which should lead to further upside for the stock.
Key Quote: “We are off to a strong start in 2018, with improved year over year performance across our portfolio that supports our full-year guidance.” Stephen Jones, President and CEO
What’s Next: Shares are down from a high of just over $17 in December. Investors can accumulate shares right now for around $15, representing a market cap of about $1.9 billion. At the company's expected 2018 revenue, this puts it at just around 1x sales. For a company producing double-digit growth and positive net income, the multiple should be much higher.
AtriCure Inc. (NASDAQ: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced its 1Q 2018 financial results.
Worldwide revenue of $47.0 million, an increase of 13.9% YoY
U.S. revenue of $38.4 million, an increase of 15.5% YoY
International revenue of $8.6 million, an increase of 6.9% YoY
Key Quote: “We are pleased with our first quarter performance and meaningful progress toward completing enrollment in CONVERGE.” Mike Carrel , President and CEO, AtriCure Inc.
The Backstory: AtriCure Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib-related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 125,000 implanted to date. For more information, visit AtriCure.com. Follow AtriCure on Twitter: @AtriCure.
Achaogen Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has entered into an award agreement with CARB-X. Under the agreement, Achaogen will receive an initial award of up to $2.4 million, with the possibility of up to $9.6 million more from CARB-X at its discretion based on the achievement of certain project milestones.
Why It Matters: The collaboration will focus on the development of a next-generation, broad-spectrum aminoglycoside antibiotic capable of overcoming clinically relevant resistance mechanisms and potentially treating highly resistant gram-negative pathogens such as the Enterobacteriaceae family, Acinetobacter baumannii, and Pseudomonas aeruginosa.
In 2017, the World Health Organization (WHO) recognized multi-drug resistant P. aeruginosa, A. baumannii and various Enterobacteriaceae as “Priority 1 critical pathogens” that pose the greatest threat to human health.
The Backstory: Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin the breakthrough therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options.
Portola Pharmaceuticals Inc.® (NASDAQ: PTLA) announced April 25 that new interim results from the Company’s ongoing Phase 2a study of cerdulatinib in patients with non-Hodgkin’s lymphoma (NHL), including B-cell NHL and relapsed/refractory peripheral T-cell lymphoma (PTCL), will be presented during a poster discussion session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, in Chicago.
Why It Matters: Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor that uniquely inhibits two key cell-signaling pathways that in certain hematologic malignancies promote the growth of cancer cells. It is being developed for the treatment of resistant or relapsed hematologic cancer.
The Backstory: Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine, Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. For more information, go to www.portola.com.
Akcea Therapeutics Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals Inc., today announced that data from inotersen’s clinical-development program for the treatment of hereditary ATTR (hATTR) amyloidosis will be presented April 21-27 at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles.
Key Quote: “We are pleased to have the opportunity to present data from the NEURO-TTR study in two oral presentations at this year’s American Academy of Neurology Annual Meeting. These data, combined with the sustained efficacy in the open label extension study, continue to demonstrate that inotersen has the potential to significantly benefit people living with hATTR amyloidosis.” Sarah Boyce, President, Akcea Therapeutics.
Why It Matters: hATTR amyloidosis is a progressive, systemic, and fatal genetic disease caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs throughout the body, including in the peripheral nerves, heart, intestinal tract, eyes, and kidneys. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to sensory, motor, and autonomic dysfunction. hATTR amyloidosis results in death within three to 15 years of symptom onset.
The Backstory: Inotersen is an antisense drug designed to reduce the production of transthyretin, or TTR protein, to treat ATTR amyloidosis. Inotersen is currently under priority review for marketing authorization in the U.S. and accelerated assessment in the EU. The U.S. Food and Drug Administration has granted inotersen the orphan drug designation and fast-track status, and the European Medicines Agency has granted inotersen orphan drug designation.
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs, including inotersen, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, all with the potential to treat multiple diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Cambridge, Mass. For more information, see www.akceatx.com.
In recent years, investors have flocked to exchange-traded funds (ETFs). This popular means for investors to gain easy exposure to diverse asset classes and strategies could actually pose a risk for some assets.
According to FactSet, U.S.-listed stock ETFs have surged to $2.8 trillion in value. As predominantly passive products, ETFs are causing rises and falls in underlying stocks simply from the buying and selling of the ETFs themselves.
When you take this fact to the small-cap space, where stocks often have lower liquidity levels, the moves can become exaggerated. And after a multi-year runup in small-cap indexes, the potential for exaggerated moves to the downside is large.
Of course, this is something that only impacts stocks that are owned by ETFs. The vast majority of microcap stocks, and nearly all of the stocks we feature at RedChip, are not members of indexes like the Russell 2000. Therefore, they are immune to these potential external forces.
Editor’s note: John Lowy wrote the article below, and John has given RedChip permission to publish his piece. The piece originally ran in the Spring 2018 issue of MicroCap Review. John is the founder and CEO of Olympic Capital Group Inc. (www.ocgfinance.com), and is the principal of his law firm John B. Lowy P.C. (www.johnlowylaw.com). John is an expert in reverse mergers, capital formation, financial consulting, and initial public listings of all types.
The latest investor fad—which comes shortly after the excitement about cannabis deals—is about cryptocurrencies/blockchain deals. So, should a public company do a reverse merger with a privately-owned “Crypto Company”? And conversely, should a privately owned Crypto Company go public via reverse merging with a U.S. publicly-held company?
Currently, I am representing one publicly-held SEC-reporting issuer whose principal acquired control of the public company before the public company embarked on its crypto business plan. Also, I am working with other private companies which may elect to go public via a reverse merger. I am also aware of a Regulation A offering of an equity token, and an S-1 for an Initial Coin Offering (“ICO”), as well as several private “SAFT“ (Simple Agreement for Future Tokens) offerings.
For purposes of this article, I have assumed that almost all ICOs and SAFTs would be considered “securities” by the SEC; and therefore, when the public company reverse merges with a crypto company, its future offerings of ICOs and SAFTs, if any, would have to be registered with the SEC or legally exempt from registration. I’m also assuming that the crypto company has an ongoing business of its own, as opposed to predominantly investing in other crypto currencies, which might require registering under the Investment Company Act of 1940. However, neither the reverse merger itself, nor ordinary trading in shares of the reverse-merged public company, would be considered a new offering of securities.
When considering a reverse merger between a public company and a private crypto company, probably the most important consideration is that the SEC is carefully reviewing all filings and press releases related to any company in the blockchain/crypto business. So, there needs to be appropriate and continuing disclosure about the company’s business, management’s experience, and how they actually intend to build or have built a viable business. Another important consideration is the selection of the PCAOB-registered auditor; many accounting firms are reticent to audit crypto companies, because, among other issues, it may be difficult to value the tokens.
The SEC is especially watching for companies trying to ride the wave and hype with no experience or viable business plan. The smartest thing to do is to include a lot of risk factors in the Super 8-K and both quarterly reports on Form 10-Q and the Annual Report on Form 10-K about the technology and area in general, and to reference them and/or provide links to the risk factors in other public disclosures, such as press releases, blogs, the company’s website, etc. Specifically, those risk factors should include the SEC’s scrutiny of the sector, the risk that the entire cryptocurrency industry could either collapse or be regulated out of existence, potential problems in opening bank accounts, etc.
It’s quite conceivable that a reverse-merged crypto company could receive a lot more publicity, sometimes not favorable, and might trade actively, simply by being in this sector; for example, look at the trading volume and notoriety about Riot Blockchain (symbol RIOT). So, to state the obvious, (a) publish continual and—above all—accurate—information about the company, (b) file all SEC reports on a timely basis, (c) avoid the “pump” part of pump and dump, and (d) don’t even think about being involved with the “dump” part of pump and dump—that’s a quick ticket to Camp Fed.
I also recommend that another way to cope with any unusual market activity, which is likely to occur in the crypto sector, is to hire experienced Investor Relations people, both in-house and out-house (oops, I mean independent), to provide and review the ongoing IR program. The independent IR firm should be reputable and have experience with crypto companies. All public announcements should be reviewed by outside counsel, and, if appropriate, by the company’s auditor.
One of the main reasons why private companies go public is to have better access to capital. In my view, it is far more advisable for a private crypto company that wants to raise capital to do a reverse merger and then raise capital via a Rule 506(b) or 506(c) offering, as opposed to attempting an ICO, which would—in my opinion—take a very long time to be declared effective.
So, if a crypto company wants to become publicly traded by reverse merging, is it part of the craze, or is it crazy? For me, the bottom line is that if the public company is looking for a good private company with which to reverse merge, and assuming that the private crypto company has a viable business—not just an unsupported story—experienced management, a reputable PCAOB-registered auditor, and observes the do’s and don’ts noted in this article (and probably others), then the newly public crypto company should be on the way toward being a successful public company.
Many thanks to Laura Anthony, Esq., for her contribution and insights.
881 words
Dollar Turns Positive for 2018, Unlikely Change in Interest Rates
The U.S. economy has shown more signs of strength in 2018 than other developed economies.
According to Morgan Stanley, “The key U.S.-dollar driver has been the divergence between economic data in the U.S. and the rest of the world, and U.S. data continues to look comparatively robust.”
In addition, markets do not expect a change in interest rates ahead of the Federal Reserve meeting on Wednesday, but analysts will be closely monitoring the language and key indications from the Federal Reserve.
Also, market watchers are focused on Friday’s employment report for April for further indications of the strength of the U.S. economy and inflation pressures, which could lend even more support to the U.S. dollar.
A recent Q&A in USA Today discusses the pluses and minuses of investing in small-caps. The questioner, who reports his age as 30, asks Motley Fool writer Matthew Frankel, “Should I put most of my money (for my 401[k]) in a small-cap fund, since they tend to beat large-cap funds over time?”
Frankel answers that small-caps don’t necessarily beat large-caps over time: “From 1979 through 2015,” Frankel writes, “the broad small-cap Russell 2000 index produced annualized total returns of 11.4%, while the benchmark large-cap S&P 500 index produced an even better 11.7% annualized, and with significantly lower volatility.”
Why, then, should our young investor choose small-caps at all? One reason, Frankel says, is that small-caps have more room to grow: “[I]t’s typically far easier for a company with a $1 billion market cap to double in size than it is for, say, Microsoft,” Frankel writes.
The trick is to find the right small-cap stocks. RedChip exists to find the right small-cap stocks.
RedChip calls attention to small-cap and microcap companies that may be poised for dazzling returns, returns that a blue-chip company would be unlikely to produce.
The motto of RedChip, “Discovering Tomorrow’s Blue Chips Today,” offers a hint as to why small-caps need to form a part of your portfolio. To get a piece of the next Apple or Amazon, and the amazing returns early investors in those companies have enjoyed, you need exposure to small-caps.
Small-caps require time, care, study. RedChip spends all its time studying small-caps. Let us help inform you as you navigate the exciting world of emerging companies. Let us be a tool in your investment toolbox.
Spectrum Global Solutions (OTC: SGSI), a single-source provider of end-to-end, next-generation wireless and wireline network solutions to the service provider (carrier) and corporate enterprise markets, continues to add to its contract backlog. Last week they announced another $1.5 million in new contract awards from a Tier 1 carrier. The work is already underway, and the revenue is expected to be realized in Q2 and Q3. On May 1, they announced another $1.9 million in contracts, with work underway and expected to be fully realized during the same periods. The company also retired an additional 92 million shares last week, bringing the total to more than 210 million shares retired over the last few weeks.
Why It Matters: SGSI has been reporting a steady stream of contract wins in recent months. With the extensive history of work for major carriers and enterprise customers, and extremely favorable industry trends, we see no reason for this momentum to slow. Combine this with the additional share reduction, and we could see big upside in the months ahead.
Key Quote: “We continue to see an increase in client orders for the pre-construction services necessary to support future small cell densification, distributed antenna systems (DAS) and 5G wireless technology projects and investigation and maintenance of existing telecommunication structures.” Roger Ponder, CEO
What’s Next: We’ve been talking about SGSI for several weeks now. As of April 30, the stock has nearly doubled in value from its average price over the period. But it's still only a $5.3 million market cap. The company is expected to generate upwards of $30 million in revenue in 2018. Even at a conservative valuation of 1x sales, the stock could still see several hundred percent gains in the near-term.
Disclosure
(Spectrum Global Solutions [OTC: SGSI] is a client of RedChip Companies, Inc. SGSI agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.)
Canopy Growth (TSX: WEED), a world-leading diversified cannabis and hemp company, last week joined the state government of Victoria (Australia) to announce the launch of its newest venture, Spectrum Cannabis Australia.
Why It Matters: Based on its track record in other markets including South America and Europe, the company has proven its ability to supply reliable and high quality medicinal cannabis products. The launch of Spectrum Australia takes that experience to a new market, building on Canopy Growth's leadership position in the global medical cannabis space.
Key Quote: “Victoria is now home for Spectrum as we introduce our world-renowned medical cannabis products to the state, across Australia, and throughout the entire APAC region, as jurisdictions establish legal, regulated medical-cannabis regimes.” Ben Quirin, Managing Director, Spectrum Australia.
What’s Next: Canopy Growth’s success paves the way for others in this rapidly evolving market. If you’re playing cannabis stocks, it’s one to consider, but as a leader in the industry, it commands a significant premium for its valuation. Its biggest gains may already be behind it. Early investors that bought when it was a microcap three years ago, if they’re still holding, are up thousands of percent. So while it may be part of your cannabis portfolio, if you’re looking for the types of gains smaller-cap stocks can be known to produce, you’ll want to also pick up some smaller names, as for example Green Spirit Industries (OTC: GSRX).
Disclosure
(Green Spirit Industries [OTC: GSRX] is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services and 50,000 shares for investor awareness services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.)
Alpine 4 Technologies (OTCQB: ALPP) announced that it is providing preliminary guidance for its Q1 2018 sales. The company said that for the period ending Q1 2018 it expects to report sales of roughly $3.6 million, which is growth of approximately 44% over Q1 2017 and by approximately 16% over Q4 2017.
Key Quote: “We knew Q1 2018 would be a record quarter for Alpine 4 and our subsidiaries. We are excited to begin Q2 and expect things to build upon the success of Q1 and for 2018 to be our year of rapid growth.” Kent B. Wilson, Alpine 4 CEO
The Backstory: ALPP is a fast-growing technology-driven holding company forecasted to generate an estimated $67 million in annualized revenue by FY18; these estimates are driven by adding two new acquisitions (signed LOIs) by Q1 2018 with a total forecasted annualized revenue of $43 million and organic growth of $26 million annualized revenue from their existing subsidiaries.
The goal of the Company is to allow these high-growth subsidiaries to organically develop their own identities and synergistically prosper from inter-company resources, while ALPP controls interest in every subsidiary and has direct control over planning and management. The Company's portfolio approach provides investors access to unique opportunities with the potential for significant upside while reducing risk through diversification.
Disclosure
(Alpine 4 Technologies [OTCQB:ALPP] is a client of RedChip Companies. ALPP agreed to pay RedChip a monthly cash fee and 400,000 shares of restricted Class A common stock for six months of investor awareness services.)
Esports Entertainment Group, Inc. (OTCQB: GMBL), a licensed online gambling company with a specific focus on esports wagering and 18+ gaming, appointed UHY McGovern Hurley LLP as its auditor last week, replacing PLS CPA.
Why It Matters: Part of an international network of accounting and consulting firms with 320 offices across 95 countries, UHY provides the necessary resources for a company like GMBL that operates internationally (offices and licenses in North America, Caribbean, and Europe) and is expecting rapid growth with further geographic expansion anticipated in the future.
Key Quote: “UHY is recognized as a leader providing audit services to industry worldwide, and we are pleased to work with a firm that truly understands our global needs.” Grant Johnson, CEO
What’s Next: Esports wagering is expected to explode to more than $23 billion by 2020. GMBL makes money by matching bettors. Win or lose, GMBL makes money. Gaining just a fraction of the potential $23 billion in esports wagering will bode extremely well for GMBL and its shareholders. And right now, it’s still a ground-floor opportunity. Their platform just went live in March.
Disclosure
(Esports Entertainment Group, Inc. [OTCQB: GMBL] is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.)
183 words
Quote of the Week
"Don't put too much money in any one stock, spread it out,
you never know which ones will be your big winner."
Buzz Heidkte, Owner MidSouth Investor Fund
IDXG Fact Sheet: Interpace Diagnostics (NASDAQ: IDXG) is a fully integrated commercial organization that provides clinically useful molecular diagnostic tests and pathology services for evaluating the risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. - March 2018
TPIV Fact Sheet: TapImmune (NASDAQ: TPIV) develops immunotherapies targeting tumors and metastatic diseases for a variety of cancers. The Company's next-generation technology has been engineered to overcome the deficiencies of earlier cancer-vaccine approaches. - March 2018
IMRN Fact Sheet: Immuron Ltd (NASDAQ: IMRN) is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that can generate a wide range of products, all with a high safety profile. - March 2018
DGLY Fact Sheet: Digital Ally® (NASDAQ: DGLY) headquartered in Lenexa, Kan., specializes in the design and manufacture of the highest-quality video-recording equipment and video-analytic software. In industries such as law enforcement, emergency management, commercial fleets, and consumer use, Digital Ally pushes the boundaries of technology. - March 2018
CATS Fact Sheet: Catasys Inc. (NASDAQ: CATS) harnesses proprietary big-data predictive analytics, artificial intelligence, and telehealth. These elements, combined with human intervention and integrated, technology-enabled treatment solutions, deliver improved health to members and cost savings to health plans- March 2018
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.
